BioCryst Pharmaceuticals BCRX Royalty financing obligations
Royalty financing obligations at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept bcrx:RoyaltyFinancingLiabilitiesNoncurrent.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's royalty financing obligations.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's royalty financing obligations?
- BioCryst Pharmaceuticals (BCRX) reported royalty financing obligations of $407.18M in Q1 2026.
- How has BioCryst Pharmaceuticals's royalty financing obligations changed year-over-year?
- BioCryst Pharmaceuticals's royalty financing obligations decreased by 12.7% year-over-year, from $466.61M to $407.18M.
- What is the long-term trend for BioCryst Pharmaceuticals's royalty financing obligations?
- Over 2 years (2023 to 2025), BioCryst Pharmaceuticals's royalty financing obligations has grown at a -8.3% compound annual growth rate (CAGR), from $508.03M to $427.23M.
- What does royalty financing obligations mean?
- This represents the long-term portion of obligations resulting from royalty financing agreements, where future revenue streams are pledged to repay capital provided by third-party investors. It reflects the company's long-term debt burden incurred to fund research and development without immediate equity dilution. Analyzing this metric helps investors understand the long-term cost of capital and the extent to which future product revenues are encumbered.